GlycoMimetics
Gaithersburg
About GlycoMimetics
GlycoMimetics, Inc., a biopharmaceutical company, engages in the design and development of small molecule therapeutics to mimic the functions of bioactive carbohydrates. Its products include GMI-1070, a synthetic glycomimetic molecule designed to inhibit selectin types, such as E, P, and L-selectin; and GMI-1051, a small molecular weight compound for the treatment or prevention of infections caused by pseudomonas aeruginosa. The company was founded in 2003 and is based in Gaithersburg, Maryland. GlycoMimetics, Inc. acquired by Crescent BioPharma in an Reverse Merger, where GlycoMimetics changed its name to Crescent BioPharma, Inc.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Delisted
- Employees: 11 – 50
- Total funding: $373.4M
- Funding stage: M&A
- Last round: Post-IPO Equity (Sep 2017)
- Ticker: nasdaq:GLYC
- Website: glycomimetics.com
- Phone: +1 240-243-1207
Industries & Categories
Biotechnology, Health Care, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/glycomimetics-3513 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.